Loading clinical trials...
Loading clinical trials...
A Phase 1 Randomized, Placebo-Controlled, Blinded Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ARC-001 in Participants Undergoing Third Molar Extraction
The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: 1. How much of the investigational product is absorbed in the blood? 2. Are there side effects?
Age
18 - 55 years
Sex
ALL
Healthy Volunteers
No
CenExel JBR
Salt Lake City, Utah, United States
Start Date
February 26, 2025
Primary Completion Date
February 1, 2026
Completion Date
February 1, 2026
Last Updated
March 11, 2025
30
ESTIMATED participants
ARC-001
DRUG
Placebo gel
DRUG
Lead Sponsor
Arcato Laboratories, Inc.
NCT06515691
NCT06778629
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07436546